Understanding COVID-19 vaccine confidence in people living with HIV in Canada
As provinces across Canada begin to roll out third doses of COVID-19 vaccines, information about who qualifies for additional or booster doses is coming at us faster than you can say immunocompromised. But are we immunocompromised? Do we need a booster or a third dose? Is there a difference?
A new national study, called HIVCOV (CTN 328), will assess COVID-19 vaccine immune responses and effectiveness among people living with HIV
Our Resource Library is a place to share documents, videos, and training resources about HIV and STBBI research and related topics.
There are no results message
The CTN+ supports clinical trials, implementation science projects, and non-interventional research of the highest scientific and ethical standards.
Mapping Opportunities for HPV Vaccination and Screening Engagement and Uptake in Trans Men and Gender Non-Binary Individuals Assigned Female at Birth
A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living with HIV
Understanding COVID-19 vaccine confidence in people living with HIV in Canada: A pan-Canadian survey
Immunogenicity outcomes in people living with HIV following vaccination for COVID-19 (HIV-COV)
A multicenter, randomized controlled trial of the efficacy, safety and immunogenicity of the 9-valent human papillomavirus (HPV) vaccination in preventing recurrence of high-grade anal dysplasia in HIV-positive men who have sex with men (MSM)
Our researchers and trainees have produced hundreds of peer-reviewed publications in a wide range of HIV- and STBBI-related areas.